HER2 is an epidermal growth factor receptor family protein overexpressed in approximately 30% of cases of ovarian cancer, breast cancer, and other types of cancers, and its overexpression is related to poor prognosis, tumor metastasis and relapse, chemotherapeutic resistance, and low survival rate. This evidence concerns the gene ERBB2 and neoplasm.